论文部分内容阅读
肺癌的传统疗法效果不够理想,用抗体治疗肺癌是一较为有效的方法。目前主要有5类抗体用于治疗肺癌:(1)西妥昔单抗(Cetuximab)、ABX-EGF(Panitumumab)、Matuzumab(EMD72000)和曲妥珠单抗(Herceptin)等,这类抗体通过结合肿瘤细胞表面分子抑制细胞生长,具有较好的疗效,是目前研究的热点;(2)贝伐单抗(Bevacizumab),通过抑制肿瘤新生血管形成,阻断肿瘤的营养来源和转移通道,达到治疗肿瘤的目的;(3)BEC2、3F6和3F6ScFv,它们作为治疗性抗独特型抗体疫苗可以激活免疫系统,诱导抗肿瘤反应,临床应用还有待进一步研究;(4)抗体偶联效应分子,如90Y-CC49、131I-chTNT和5F11-DOX可以靶向杀伤,作用更有针对性,减少正常组织受损;(5)Catumaxomab(removab)和OKT3×Antag2,作为双特异性抗体可以联接肿瘤细胞和免疫效应细胞,增强杀伤作用。抗体治疗肺癌可以弥补传统治疗的不足,抗体治疗与传统治疗联合应用可有效提高对肺癌的疗效。
The traditional treatment of lung cancer is not ideal, with antibodies to treat lung cancer is a more effective method. There are currently five major classes of antibodies used to treat lung cancer: (1) Cetuximab, ABX-EGF (Panitumumab), Matuzumab (EMD72000) and Herceptin, (2) Bevacizumab can inhibit the neovascularization of tumor, block the tumor’s nutrition source and metastasis pathway, and achieve the goal of treatment. (2) Bevacizumab can inhibit the growth of tumor cells and has good curative effect. The purpose of the tumor; (3) BEC2, 3F6 and 3F6ScFv, they as a therapeutic anti-idiotypic antibody vaccine can activate the immune system to induce anti-tumor response, clinical application remains to be further studied; (4) antibody coupling effector molecules such as 90Y (5) Catumaxomab (removab) and OKT3 × Antag2, as bispecific antibodies, can be used to connect tumor cells and immune system Effect of cells, enhance the killing effect. Antibody treatment of lung cancer can make up for the lack of traditional treatment, antibody therapy combined with traditional therapies can effectively improve the efficacy of lung cancer.